{"id":100502,"date":"2023-08-31T11:47:02","date_gmt":"2023-08-31T11:47:02","guid":{"rendered":"https:\/\/oncogen.oncoserv.ro\/?post_type=project&p=100502"},"modified":"2023-09-06T08:34:38","modified_gmt":"2023-09-06T08:34:38","slug":"proiectul-decode","status":"publish","type":"project","link":"https:\/\/oncogen.ro\/ro\/project\/proiectul-decode\/","title":{"rendered":"Proiectul DECODE"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.22.1″ _module_preset=”default” custom_padding=”0px|0px|0px|0px|true|true” global_colors_info=”{}”][et_pb_row column_structure=”3_5,2_5″ use_custom_gutter=”on” gutter_width=”2″ make_equal=”on” _builder_version=”4.22.1″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”][et_pb_column type=”3_5″ _builder_version=”4.22.1″ _module_preset=”default” background_enable_image=”off” background_size=”contain” global_colors_info=”{}”][et_pb_image src=”https:\/\/oncogen.oncoserv.ro\/wp-content\/uploads\/2023\/09\/DECODE-POZA.jpg” title_text=”DECODE POZA” _builder_version=”4.22.1″ _module_preset=”default” hover_enabled=”0″ border_radii=”on|10px|10px|10px|10px” global_colors_info=”{}” sticky_enabled=”0″][\/et_pb_image][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=” \/\/ Proiect ” content_max_width=”100%” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|600||on|||||” header_font_size=”20px” body_font=”|700||on|||||” body_text_color=”#000000″ body_font_size=”40px” header_font_size_tablet=”” header_font_size_phone=”18px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”29px” body_font_size_last_edited=”on|phone” custom_css_blurb_title=”color:var(–color-1);padding-bottom:15px;” custom_css_blurb_content=”line-height:45px;color:var(–color-2);” global_colors_info=”{}” custom_css_blurb_content_last_edited=”on|phone” custom_css_blurb_content_phone=”line-height:39px;color:var(–color-2);” custom_css_blurb_content_tablet=”line-height:45px;color:var(–color-2);”]<\/p>\n

Proiectul DECODE<\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Durata proiectului” content_max_width=”100%” module_class=”dct_ptf_dt” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”20px” body_font=”|600|||||||” body_font_size=”17px” global_colors_info=”{}”]<\/p>\n

18 luni<\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Contract de finan\u021bare” content_max_width=”100%” module_class=”dct_ptf_dt” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”20px” body_font=”|600|||||||” body_font_size=”17px” global_colors_info=”{}”]<\/p>\n

Nr. 11Sol\/2020<\/span><\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Coordonator” content_max_width=”100%” module_class=”dct_ptf_dt” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”20px” body_font=”|600|||||||” body_font_size=”17px” global_colors_info=”{}”]<\/p>\n

Spitalul Clinic Jude\u021bean de Urgen\u021b\u0103 \u201ePius Br\u00e2nzeu\u201d Timi\u0219oara, Centrul de Terapii
Genice \u0219i Celulare \u00een Cancer \u2013 OncoGen<\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Partener” content_max_width=”100%” module_class=”dct_ptf_dt” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”20px” body_font=”|600|||||||” body_font_size=”17px” global_colors_info=”{}”]<\/p>\n

Institutul Na\u021bional de Cercetare-Dezvoltare Medico-Militar\u0103 \u201eCantacuzino\u201d<\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Detalii proiect” content_max_width=”100%” module_class=”dct_ptf_dt” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”20px” body_font=”|600|||||||” body_font_size=”17px” custom_margin=”||40px||false|false” global_colors_info=”{}”]<\/p>\n

PDF<\/a><\/p>\n

[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Sumarul proiectului” content_max_width=”100%” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”26px” body_font_size=”17px” body_line_height=”29px” global_colors_info=”{}”]<\/p>\n

Dezvoltarea unui vaccin peptidic profilatic pentru COVID-19 bazat pe epitopi recunoscu\u021bi de sistemul imun (DECODE)<\/span><\/strong><\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Obiectivele specifice” content_max_width=”100%” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”26px” body_font_size=”17px” body_line_height=”29px” global_colors_info=”{}”]<\/p>\n

    \n
  1. \u00a0<\/span>Dezvoltarea unui vaccin candidat cu eficien\u021b\u0103 dovedit\u0103 fa\u021b\u0103 de SARS-CoV-2 \u00een studii preclinice avansate \u0219i a unor poten\u021biali adjuvan\u021bi capabili s\u0103 poten\u021beze ac\u021biunea vaccinului \u0219i a procesului de imunizare, f\u0103r\u0103 a induce efecte adverse;<\/li>\n
  2. Dezvoltarea unor studii\u00a0<\/span>in vivo<\/em>, pe modele animale, \u00een vederea elucid\u0103rii mecanismelor etiopatogenice ale virusului SARS-CoV-2 \u0219i a combaterii acestora cu ajutorul unor poten\u021biale vaccinuri;<\/li>\n
  3. Elaborarea documenta\u021biei necesare unor studii clinice de faza I\/II \u00een vederea test\u0103rii poten\u021bialelor vaccinuri.<\/li>\n<\/ol>\n

    [\/et_pb_blurb][et_pb_blurb content_max_width=”100%” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”26px” body_font_size=”17px” body_line_height=”29px” global_colors_info=”{}”]<\/p>\n

    Noutatea<\/strong><\/span>\u00a0<\/span>acestui proiect rezid\u0103 \u00een faptul c\u0103 vaccinul se bazeaz\u0103 pe utilizarea unor peptide lungi sintetice imunogene (synthetic long peptide \u2013 SLP), ob\u021binute din structura proteinei S a virusului SARS-CoV-2, care activeaz\u0103 specific limfocitele T helper, T citotoxice \u0219i limfocitele B, \u00eentr-o manier\u0103 dependent\u0103 de fenotipul popula\u021bional (molecule din sistemul major de histocompatibilitate \u2013 MHC clasa I \u0219i clasa II).<\/p>\n

    Centrul OncoGen a fost inclus la 4 aprilie 2020, \u00een lista institu\u021biilor care dezvolt\u0103 un vaccin \u00eempotriva SARS-CoV-2, de c\u0103tre Organiza\u021bia Mondial\u0103 a S\u0103n\u0103t\u0103\u021bii (OMS).\u00a0<\/p>\n

    [\/et_pb_blurb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/oncogen.ro\/wp-content\/uploads\/2023\/08\/coronavirus_v2-300×290-1.jpg” title_text=”coronavirus_v2-300×290″ align=”center” _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

    Fig.1. Modalitatea de ac\u021biune la nivelul sistemului imun a vaccinului propus<\/em><\/p>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb content_max_width=”100%” _builder_version=”4.22.1″ _module_preset=”default” header_font=”|700||on|||||” header_font_size=”26px” body_font_size=”17px” body_line_height=”29px” global_colors_info=”{}”]<\/p>\n

    Proiec\u021biile cele mai optimiste de control al pandemiei COVID-19 includ o combina\u021bie a m\u0103surilor care s-au dovedit eficiente \u00een trecut: m\u0103suri sociale de control al transmisiei, noi medicamente antivirale pentru tratamentul simptomelor \u0219i dezvoltarea unui vaccin care s\u0103 previn\u0103 infec\u021bia persoanelor la risc sau dezvoltarea unor forme severe de boal\u0103. Medicamentele antivirale vor limita \u00eenc\u0103rcarea sistemului de s\u0103n\u0103tate, iar screening-ul popula\u021biei va permite men\u021binerea \u00een activitate a indivizilor care prezint\u0103 imunitate, dar transmisia bolii va fi oprit\u0103 doar de dezvoltarea \u0219i administrarea unui vaccin.<\/p>\n

    Nu se \u0219tie \u00eenc\u0103 dac\u0103 un vaccin \u00eempotriva SARS-CoV-2 va conferi imunitate pe termen lung sau scurt deoarece au r\u0103mas \u00eenc\u0103 multe lucruri de descifrat legate de patogeneza acestei infec\u021bii virale \u0219i de reac\u021bia sistemului imun fa\u021b\u0103 de virus. Spre deosebire de virusurile gripale, coronavirusul nu acumuleaz\u0103 at\u00e2t de frecvent muta\u021bii \u0219i nu prezint\u0103 dec\u00e2t un punct cheie de interac\u021biune cu celulele-gazd\u0103, proteina S, care este \u021binta majorit\u0103\u021bii strategiilor propuse de vaccin. Prin urmare, exist\u0103 motive s\u0103 consider\u0103m ca un vaccin ar putea ac\u021biona \u00een mod eficient \u0219i util. Pandemia de coronavirus a cauzat o destabilizare economic\u0103 global\u0103 \u0219i o recesiune comparabil\u0103 cu Marea Criz\u0103 Economic\u0103 din 1930, din care putem \u00eencepe s\u0103 ne revenim doar odat\u0103 cu asigurarea imunit\u0103\u021bii popula\u021biei care s\u0103 poat\u0103 fi astfel reintegrat\u0103 \u00een via\u021ba economic\u0103 activ\u0103. Imunitatea se poate asigura doar prin vaccinarea efectiv\u0103 a \u00eentregii popula\u021bii care nu a fost infectat\u0103. Alternativ, virusul va deveni \u00een timp endemic, sezonier, cauz\u00e2nd boala, uneori letal\u0103, p\u00e2n\u0103 la dob\u00e2ndirea imunit\u0103\u021bii naturale a popula\u021biei, care va fi astfel periodic incapacitat\u0103. Chiar dac\u0103, cel mai devreme, un vaccin anti-SARS-CoV-2 va fi disponibil peste 18 luni, el este necesar pentru \u00eendep\u0103rtarea complet\u0103 a spectrului sumbru pe care aceast\u0103 epidemie \u00eel genereaz\u0103 asupra sistemului de s\u0103n\u0103tate \u0219i desf\u0103\u0219ur\u0103rii activit\u0103\u021bilor sociale \u0219i economice normale.<\/p>\n

    Cea mai apropiat\u0103 dat\u0103 la care putem considera c\u0103 un vaccin va fi disponibil nu este mai devreme de 18 luni deoarece trebuie respectate protocoale care ne asigur\u0103 de eficien\u021ba \u0219i siguran\u021ba unei poten\u021biale terapii aplicate la om. \u00cen primul r\u00e2nd, trebuie aleas\u0103 o parte din virus care s\u0103 fie recunoscut\u0103 de sistemul imun \u0219i s\u0103 ini\u021bieze o reac\u021bie protectiv\u0103; aceast\u0103 protein\u0103 viral\u0103 trebuie, de asemenea, s\u0103 nu difere \u00eentre variantele circulante ale virusului \u0219i s\u0103 confere protec\u021bie pentru toate \u0219i pentru majoritatea popula\u021biei. Odat\u0103 ce acest imunogen este selectat, trebuie testat pe celule umane izolate \u0219i pe animale de laborator pentru a demonstra c\u0103 nu este toxic \u0219i c\u0103 are un efect pozitiv de stimulare a imunit\u0103\u021bii.<\/p>\n

    Majoritatea strategiilor de vaccinare \u00eempotriva infec\u021biei cu SARS-CoV-2 care sunt \u00een prezent \u00een dezvoltare utilizeaz\u0103 platforme pre-existente, cum ar fi vectori virali non-replicativi, ADN, RNA, virus inactivat sau subunit\u0103\u021bi proteice. Vaccinul propus de Spitalul Clinic Jude\u021bean de Urgen\u021b\u0103 \u201ePius Br\u00e2nzeu\u201d Timi\u0219oara (Centrul OncoGen) \u00een parteneriat cu Institutul Na\u021bional de Cercetare Medico-Militar\u0103 \u201cCantacuzino\u201d utilizeaz\u0103 peptide sintetice lungi (SLPs), o strategie de vaccinare derivat\u0103 din terapia oncologic\u0103, care va stimula apari\u021bia unui r\u0103spuns imun prin limfocite T, mai ales limfocite T citotoxice, capabile s\u0103 distrug\u0103 celulele infectate viral. Peptidele sintetice lungi vaccinale sunt fragmente din proteina S (spike) a SARS-CoV-2, selectate specific imunofenotipului popula\u021biei din Rom\u00e2nia. Secundar, strategia noastr\u0103 cu peptide sintetice lungi stimuleaz\u0103 imunitatea umoral\u0103 \u0219i apari\u021bia anticorpilor protectivi \u00eempotriva SARS-CoV-2.<\/p>\n

    Parteneriatul dintre Centrul OncoGen din cadrul Spitalului Clinic Jude\u021bean de Urgen\u021b\u0103 \u201ePius Br\u00e2nzeu\u201d Timi\u0219oara \u0219i Institutul Na\u021bional de Cercetare Medico-Militar\u0103 \u201cCantacuzino\u201d s-a concretizat \u00een c\u00e2\u0219tigarea acestui proiect de cercetare prin competi\u021bie na\u021bional\u0103 \u00een cadrul programului SOLU\u021aII 2020, competi\u021bie la care am participat pentru a ob\u021bine finan\u021barea necesar\u0103 efectu\u0103rii studiilor\u00a0<\/span>in vitro<\/em>\u00a0<\/span>(pe celule) \u0219i\u00a0<\/span>in vivo<\/em>\u00a0<\/span>(pe model animal) necesare dezvolt\u0103rii unui vaccin \u00eempotriva SARS-CoV-2 cu aplicabilitate la om, \u00een dorin\u021ba de a stopa, prin metode de vaccinologie modern\u0103, pandemia actual\u0103.<\/p>\n

    [\/et_pb_blurb][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” width=”100%” max_width=”100%” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/oncogen.ro\/wp-content\/uploads\/2023\/08\/secventa-500×200-1.jpg” title_text=”secventa-500×200″ align=”center” _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.22.1″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

    Fig. 2. Harta grafic\u0103 a peptidelor sintetice lungi (SLPs) componente ale vaccinului \u00eempotriva SARS-CoV-2<\/em><\/p>\n

    [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

    Proiectul DECODE18 luniNr. 11Sol\/2020Spitalul Clinic Jude\u021bean de Urgen\u021b\u0103 \u201ePius Br\u00e2nzeu\u201d Timi\u0219oara, Centrul de TerapiiGenice \u0219i Celulare \u00een Cancer \u2013 OncoGenInstitutul Na\u021bional de Cercetare-Dezvoltare Medico-Militar\u0103 \u201eCantacuzino\u201dPDFDezvoltarea unui vaccin peptidic profilatic pentru COVID-19 bazat pe epitopi recunoscu\u021bi de sistemul imun (DECODE) \u00a0Dezvoltarea unui vaccin candidat cu eficien\u021b\u0103 dovedit\u0103 fa\u021b\u0103 de SARS-CoV-2 \u00een studii preclinice avansate \u0219i a […]<\/p>\n","protected":false},"author":2,"featured_media":100829,"comment_status":"open","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"project_category":[],"project_tag":[],"_links":{"self":[{"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project\/100502"}],"collection":[{"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/comments?post=100502"}],"version-history":[{"count":6,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project\/100502\/revisions"}],"predecessor-version":[{"id":100998,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project\/100502\/revisions\/100998"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/media\/100829"}],"wp:attachment":[{"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/media?parent=100502"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project_category?post=100502"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/oncogen.ro\/ro\/wp-json\/wp\/v2\/project_tag?post=100502"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}